Alios BioPharma Presented Data on Its First-in-Class Anti-Respiratory Syncytial Virus (RSV) Nucleoside Analogs at the 8th Annual Respiratory Syncytial Virus Symposium

Source :: Internet Wire. October 1, 2012
Publication Year :: 2012
Abstract: Byline: SOUTH SAN FRANCISCO, CA, Oct 01, 2012 (MARKETWIRE via COMTEX) -- Alios BioPharma, Inc. today announced the discovery of first-in-class anti-RSV nucleoside analogs that will be developed for the [...]

Subjects :: Biological products industry -- Conferences, meetings and seminars -- Product development
Respiratory syncytial virus infection -- Care and treatment
Nucleoside analogs -- Conferences, meetings and seminars -- Product development
Business
Business, international
News, opinion and commentary

Tools